BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Votrient (Pazopanib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Votrient (Pazopanib)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06739395-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Votrient (Pazopanib): Phase 2 readout est. (NCT06739395)
DESCRIPTION:Votrient (Pazopanib)\, phase 2.\nStudy: Precision Medicine Tria
 l Based on Molecular Matching Therapy for Patients With Standard Treatment
  Exhaustion\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05679921-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Votrient (Pazopanib): Phase 2 readout est. (NCT05679921)
DESCRIPTION:Votrient (Pazopanib)\, phase 2\, Soft Tissue Sarcoma.\nStudy: P
 azopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pazopanib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05679921
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02331498-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT02331498)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2.\nStudy: Phase I/II Study of P
 azopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multi
 forme\nEstimated primary completion: February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT02331498
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180695-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT05180695)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2\, Soft Tissue Sarcoma.\nStudy:
  HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic S
 oft Tissue Sarcomas\nEstimated primary completion: February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05180695
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01684397-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT01684397)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previo
 usly Untreated Metastatic Kidney Cancer\nEstimated primary completion: 20 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pazopa
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 01684397
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02029001-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Votrient (Pazopanib): Phase 2 readout est. (NCT02029001)
DESCRIPTION:Votrient (Pazopanib)\, phase 2.\nStudy: Adapting Treatment to t
 he Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My
 OwnSpecificTreatment\nEstimated primary completion: January 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT02029001
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01217931-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Votrient (Pazopanib): Phase 2 readout est. (NCT01217931)
DESCRIPTION:Votrient (Pazopanib)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START
  Trial\nEstimated primary completion: 31 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01217931
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04199026-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Votrient (Pazopanib): Phase na readout est. (NCT04199026)
DESCRIPTION:Votrient (Pazopanib)\, phase na.\nStudy: Implantable Microdevic
 e for the Delivery of Drugs and Their Effect on Tumors in Patients With Me
 tastatic or Recurrent Sarcoma\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04199026
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444619-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Votrient (Pazopanib): Phase 1 readout est. (NCT07444619)
DESCRIPTION:Votrient (Pazopanib)\, phase 1\, Soft Tissue Sarcoma.\nStudy: A
  Phase I Study of Pazopanib in Combination With Trabectedin\, Ipilimumab a
 nd Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent
  Soft Tissue Sarcomas\nEstimated primary completion: 31 December 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07444619
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239272-1918@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20340630
DTEND;VALUE=DATE:20340701
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT06239272)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2\, Soft Tissue Sarcoma.\nStudy:
  NRSTS2021\, A Risk Adapted Study Evaluating Maintenance Pazopanib\, Limit
 ed Margin\, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomy
 osarcoma Soft Tissue Sarcoma (NRSTS)\nEstimated primary completion: June 2
 034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06239272
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
